Abbott Reports Data from the Real-World Studies of Freestyle Libre Systems and GLP-1 Therapy in Patients with Type 2 Diabetes
Shots:
- The studies used Optum's de-identified Market Clarity Data focusing on US adults with T2D & HbA1c ≥8%. The 1st study "FreeStyle Libre improves HbA1c in people receiving GLP-1 therapy for type 2 diabetes" assessed patients (n=1,781, 55±10yrs.) on GLP-1 therapy receiving 1st FreeStyle Libre b/w 2018 & 2022
- The 2nd study, "Initiating GLP-1 therapy in combination with FreeStyle Libre provides greater benefit compared to GLP-1 therapy alone," had patients receiving 1st GLP-1 b/w 2018 & 2022 who were given 1st FreeStyle Libre sensor within ±30 days of 1st GLP-1 therapy
- The 1st study showed a -1.5% improvement in HbA1C 6mos. post the addition of FreeStyle & 2nd study showed a -2.4% vs -1.7% reduction in HbA1C with GLP-1 + FreeStyle vs GLP-1
Ref: Abbott | Image: Abbott
Related News:- Abbott Introduces Protality for Adults Pursuing Weight Loss
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
